The structure of dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants
- Author
- TOKARSKI, John S1 ; NEWITT, John A1 ; DIANLIN XIE1 ; YAQUN ZHANG1 ; KLEI, Herbert E1 ; CHANG, Chieh Ying J1 ; CHENG, Janet D1 ; WITTEKIND, Michael1 ; KIEFER, Susan E1 ; KISH, Kevin1 ; LEE, Francis Y. F1 ; BORZILLERRI, Robert1 ; LOMBARDO, Louis J1
[1] Bristol-Mvers Squibb Company, Pharmaceutical Research Institute, Princeton, New Jersey, United States - Source
Cancer research (Baltimore). 2006, Vol 66, Num 11, pp 5790-5797, 8 p ; ref : 44 ref
- CODEN
- CNREA8
- ISSN
- 0008-5472
- Scientific domain
- Medical oncology; Pharmacology drugs
- Publisher
- American Association for Cancer Research, Philadelphia, PA
- Publication country
- United States
- Document type
- Article
- Language
- English
- Keyword (fr)
- Activité biologique Anticancéreux Imatinib Inhibiteur enzyme Kinase Mutation Protein-tyrosine kinase Résistance Structure Gène abl Inhibiteur tyrosine kinase Enzyme Transferases
- Keyword (en)
- Biological activity Antineoplastic agent Imatinib Enzyme inhibitor Kinase Mutation Protein-tyrosine kinase Resistance Structure Enzyme Transferases
- Keyword (es)
- Actividad biológica Anticanceroso Imatinib Inhibidor enzima Kinase Mutación Protein-tyrosine kinase Resistencia Estructura Enzima Transferases
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B02 Pharmacology. Drug treatments / 002B02R Antineoplastic agents
- Discipline
- Pharmacological treatments Tumours
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 17834701
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.1158/0008-5472.CAN-05-4187 
https://dx.doi.org/10.1158/0008-5472.CAN-05-4187
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1158\/0008-5472.CAN-05-4187\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:150:\"The structure of dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants\";s:9:\"\u0000*\u0000jtitle\";s:27:\"Cancer research (Baltimore)\";s:9:\"\u0000*\u0000stitle\";s:23:\"Cancer res. (Baltimore)\";s:7:\"\u0000*\u0000date\";s:4:\"2006\";s:9:\"\u0000*\u0000volume\";s:2:\"66\";s:8:\"\u0000*\u0000issue\";s:2:\"11\";s:8:\"\u0000*\u0000spage\";s:4:\"5790\";s:8:\"\u0000*\u0000epage\";s:4:\"5797\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0008-5472\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"TOKARSKI\";s:10:\"\u0000*\u0000aufirst\";s:6:\"John S\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:12:{i:0;s:14:\"NEWITT, John A\";i:1;s:11:\"DIANLIN XIE\";i:2;s:11:\"YAQUN ZHANG\";i:3;s:15:\"KLEI, Herbert E\";i:4;s:19:\"CHANG, Chieh Ying J\";i:5;s:14:\"CHENG, Janet D\";i:6;s:18:\"WITTEKIND, Michael\";i:7;s:15:\"KIEFER, Susan E\";i:8;s:11:\"KISH, Kevin\";i:9;s:17:\"LEE, Francis Y. F\";i:10;s:19:\"BORZILLERRI, Robert\";i:11;s:17:\"LOMBARDO, Louis J\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"CNREA8\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:150:\"The structure of dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants\";s:8:\"\u0000*\u0000place\";s:16:\"Philadelphia, PA\";s:6:\"\u0000*\u0000pub\";s:40:\"American Association for Cancer Research\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"8\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1158\/0008-5472.CAN-05-4187\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:150:\"The structure of dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants\";s:9:\"\u0000*\u0000jtitle\";s:27:\"Cancer research (Baltimore)\";s:9:\"\u0000*\u0000stitle\";s:23:\"Cancer res. (Baltimore)\";s:7:\"\u0000*\u0000date\";s:4:\"2006\";s:9:\"\u0000*\u0000volume\";s:2:\"66\";s:8:\"\u0000*\u0000issue\";s:2:\"11\";s:8:\"\u0000*\u0000spage\";s:4:\"5790\";s:8:\"\u0000*\u0000epage\";s:4:\"5797\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0008-5472\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"TOKARSKI\";s:10:\"\u0000*\u0000aufirst\";s:6:\"John S\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:12:{i:0;s:14:\"NEWITT, John A\";i:1;s:11:\"DIANLIN XIE\";i:2;s:11:\"YAQUN ZHANG\";i:3;s:15:\"KLEI, Herbert E\";i:4;s:19:\"CHANG, Chieh Ying J\";i:5;s:14:\"CHENG, Janet D\";i:6;s:18:\"WITTEKIND, Michael\";i:7;s:15:\"KIEFER, Susan E\";i:8;s:11:\"KISH, Kevin\";i:9;s:17:\"LEE, Francis Y. F\";i:10;s:19:\"BORZILLERRI, Robert\";i:11;s:17:\"LOMBARDO, Louis J\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"CNREA8\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:150:\"The structure of dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants\";s:8:\"\u0000*\u0000place\";s:16:\"Philadelphia, PA\";s:6:\"\u0000*\u0000pub\";s:40:\"American Association for Cancer Research\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"8\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:29:\"10.1158\/0008-5472.CAN-05-4187\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1158\/0008-5472.CAN-05-4187\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:150:\"The structure of dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants\";s:9:\"\u0000*\u0000jtitle\";s:27:\"Cancer research (Baltimore)\";s:9:\"\u0000*\u0000stitle\";s:23:\"Cancer res. (Baltimore)\";s:7:\"\u0000*\u0000date\";s:4:\"2006\";s:9:\"\u0000*\u0000volume\";s:2:\"66\";s:8:\"\u0000*\u0000issue\";s:2:\"11\";s:8:\"\u0000*\u0000spage\";s:4:\"5790\";s:8:\"\u0000*\u0000epage\";s:4:\"5797\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0008-5472\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"TOKARSKI\";s:10:\"\u0000*\u0000aufirst\";s:6:\"John S\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:12:{i:0;s:14:\"NEWITT, John A\";i:1;s:11:\"DIANLIN XIE\";i:2;s:11:\"YAQUN ZHANG\";i:3;s:15:\"KLEI, Herbert E\";i:4;s:19:\"CHANG, Chieh Ying J\";i:5;s:14:\"CHENG, Janet D\";i:6;s:18:\"WITTEKIND, Michael\";i:7;s:15:\"KIEFER, Susan E\";i:8;s:11:\"KISH, Kevin\";i:9;s:17:\"LEE, Francis Y. F\";i:10;s:19:\"BORZILLERRI, Robert\";i:11;s:17:\"LOMBARDO, Louis J\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"CNREA8\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:150:\"The structure of dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants\";s:8:\"\u0000*\u0000place\";s:16:\"Philadelphia, PA\";s:6:\"\u0000*\u0000pub\";s:40:\"American Association for Cancer Research\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"8\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1158\/0008-5472.CAN-05-4187\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:150:\"The structure of dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants\";s:9:\"\u0000*\u0000jtitle\";s:27:\"Cancer research (Baltimore)\";s:9:\"\u0000*\u0000stitle\";s:23:\"Cancer res. (Baltimore)\";s:7:\"\u0000*\u0000date\";s:4:\"2006\";s:9:\"\u0000*\u0000volume\";s:2:\"66\";s:8:\"\u0000*\u0000issue\";s:2:\"11\";s:8:\"\u0000*\u0000spage\";s:4:\"5790\";s:8:\"\u0000*\u0000epage\";s:4:\"5797\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0008-5472\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"TOKARSKI\";s:10:\"\u0000*\u0000aufirst\";s:6:\"John S\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:12:{i:0;s:14:\"NEWITT, John A\";i:1;s:11:\"DIANLIN XIE\";i:2;s:11:\"YAQUN ZHANG\";i:3;s:15:\"KLEI, Herbert E\";i:4;s:19:\"CHANG, Chieh Ying J\";i:5;s:14:\"CHENG, Janet D\";i:6;s:18:\"WITTEKIND, Michael\";i:7;s:15:\"KIEFER, Susan E\";i:8;s:11:\"KISH, Kevin\";i:9;s:17:\"LEE, Francis Y. F\";i:10;s:19:\"BORZILLERRI, Robert\";i:11;s:17:\"LOMBARDO, Louis J\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"CNREA8\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:150:\"The structure of dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants\";s:8:\"\u0000*\u0000place\";s:16:\"Philadelphia, PA\";s:6:\"\u0000*\u0000pub\";s:40:\"American Association for Cancer Research\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"8\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1158\/0008-5472.CAN-05-4187\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:150:\"The structure of dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants\";s:9:\"\u0000*\u0000jtitle\";s:27:\"Cancer research (Baltimore)\";s:9:\"\u0000*\u0000stitle\";s:23:\"Cancer res. (Baltimore)\";s:7:\"\u0000*\u0000date\";s:4:\"2006\";s:9:\"\u0000*\u0000volume\";s:2:\"66\";s:8:\"\u0000*\u0000issue\";s:2:\"11\";s:8:\"\u0000*\u0000spage\";s:4:\"5790\";s:8:\"\u0000*\u0000epage\";s:4:\"5797\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0008-5472\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:8:\"TOKARSKI\";s:10:\"\u0000*\u0000aufirst\";s:6:\"John S\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:12:{i:0;s:14:\"NEWITT, John A\";i:1;s:11:\"DIANLIN XIE\";i:2;s:11:\"YAQUN ZHANG\";i:3;s:15:\"KLEI, Herbert E\";i:4;s:19:\"CHANG, Chieh Ying J\";i:5;s:14:\"CHENG, Janet D\";i:6;s:18:\"WITTEKIND, Michael\";i:7;s:15:\"KIEFER, Susan E\";i:8;s:11:\"KISH, Kevin\";i:9;s:17:\"LEE, Francis Y. F\";i:10;s:19:\"BORZILLERRI, Robert\";i:11;s:17:\"LOMBARDO, Louis J\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"CNREA8\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:150:\"The structure of dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants\";s:8:\"\u0000*\u0000place\";s:16:\"Philadelphia, PA\";s:6:\"\u0000*\u0000pub\";s:40:\"American Association for Cancer Research\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"8\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
